

Laura Rosiñol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3609420/publications.pdf>

Version: 2024-02-01

57
papers

8,849
citations

186265

28
h-index

144013

57
g-index

58
all docs

58
docs citations

58
times ranked

7241
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	10.7	3,343
2	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
3	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	1.4	429
4	Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. <i>Journal of Clinical Oncology</i> , 2011, 29, 3805-3812.	1.6	302
5	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	27.0	291
6	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	1.4	274
7	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.	1.6	263
8	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	1.6	248
9	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 3279-3287.	1.6	238
10	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	1.6	175
11	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progressionâ€“Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	1.6	150
12	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.	1.4	148
13	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
14	Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	3.5	101
15	Extramedullary multiple myeloma escapes the effect of thalidomide. <i>Haematologica</i> , 2004, 89, 832-6.	3.5	100
16	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. <i>Haematologica</i> , 2017, 102, 1099-1104.	3.5	81
17	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021, 137, 49-60.	1.4	80
18	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	1.4	76

#	ARTICLE	IF	CITATIONS
19	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2001, 113, 422-424.	2.5	73
20	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	1.4	68
21	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
22	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	6.2	62
23	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	6.2	60
24	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	6.2	57
25	Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1196-1202.	2.0	50
26	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	3.5	48
27	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	1.4	41
28	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	1.6	40
29	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	1.4	24
30	Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. <i>European Journal of Haematology</i> , 2010, 85, 448-451.	2.2	23
31	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	1.4	23
32	Extramedullary disease in multiple myeloma in the era of novel agents. <i>British Journal of Haematology</i> , 2015, 169, 763-765.	2.5	21
33	Pomalidomide+dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. <i>European Journal of Haematology</i> , 2019, 102, 389-394.	2.2	21
34	Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. <i>British Journal of Haematology</i> , 2021, 193, 181-187.	2.5	20
35	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	5.2	19
36	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3234-3239.	5.2	18

#	ARTICLE	IF	CITATIONS
37	Novel drugs for the treatment of multiple myeloma. <i>Haematologica</i> , 2010, 95, 702-704.	3.5	15
38	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 619.e1-619.e8.	1.2	15
39	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
40	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	1.4	14
41	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.	7.0	14
42	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	4.1	13
43	Extramedullary Myeloma Spread Triggered by Surgical Procedures: An Emerging Entity?. <i>Acta Haematologica</i> , 2014, 132, 36-38.	1.4	12
44	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	1.4	11
45	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	3.7	11
46	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	6.2	8
47	Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2904-2910.	2.4	7
48	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 489.e1-489.e9.	1.2	7
49	Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. <i>British Journal of Haematology</i> , 2022, 196, 649-659.	2.5	6
50	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 299-306.	2.5	5
51	Real-world evidence of daratumumab monotherapy in relapsed/refractory multiple myeloma patients and efficacy on soft-tissue plasmacytomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	5
52	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. <i>Blood Cancer Journal</i> , 2022, 12, 76.	6.2	5
53	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the <scp>CANDOR</scp> study. <i>British Journal of Haematology</i> , 2022, 198, 988-993.	2.5	5
54	Plasmacytomas in Multiple Myeloma: 45-Years Experience from a Single Institution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e107.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
56	Extramedullary Plasmacytoma Over the scar from Long-lasting Past Surgery as Presenting Feature of Multiple Myeloma. <i>Archives of Clinical and Biomedical Research</i> , 2020, 04, .	0.2	2
57	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e241-e249.	0.4	2